Condition(s) treated: Acne; Inflammation

Intervention: Doxycycline (Drug)

Phase: Phase 2/Phase 3

Enrollment status: Recruiting

Sponsor: Shaheed Beheshti Medical University

Principal investigator(s) or official(s):
Parviz Toossi, M.D., Principal Investigator, Affiliation: Shaheed Beheshti Medical University

Overall contact:
Parviz Toossi, M.D., Phone: 98-21-22744392, Email: src@sbmu.ac.ir

The purpose of this study is to compare the safety and efficacy of twice daily subantimicrobial dose doxycycline 20mg with daily doxycycline 100mg in treatment of mild and moderate Acne.

Official title: The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

Study design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study

Minimum eligible age: 18 Years. Maximum eligible age: 40 Years. Eligible gender(s): Both.

Criteria:

Inclusion Criteria:

- Acne

Exclusion Criteria:

- Pregnancy

Parviz Toossi, M.D., Phone: 98-21-22744392, Email: src@sbmu.ac.ir

Skin Research Center, Shaheed Beheshti Medical University, Tehran 19899, Iran, Islamic Republic of; Recruiting
Parviz Toossi, M.D., Phone: 98-21-22744392, Email: src@sbmu.ac.ir
Parviz Toossi, M.D., Principal Investigator
Nahid Mohtasham, MD, Sub-Investigator

Start date: October 2005
End date: October 2006
Last updated: January 22, 2008

Web SmartSkinCare.com